Author:
Kang Daniel,Huang Cher X.,Yuen Alexander D.,Norris Keith C.,Vijayan Tara
Abstract
Abstract
Objectives
To compare hospitals that did and did not participate in clinical trials evaluating potential inpatient COVID-19 therapeutics.
Methods
We conducted a cross-sectional study of hospitals participating in trials that were registered on clinicaltrials.gov between April and August 2020. Using the 2019 RAND Hospital Dataset and 2019 American Community Survey, we used logistic regression modeling to compare hospital-level traits including demographic features between trial and non-trial hospitals.
Results
We included 488 hospitals that were participating in 298 interventional trials and 4232 non-participating hospitals. After controlling for demographic and other hospital traits, we found that teaching status (OR 2.11, 95% CI 1.52–2.95), higher patient acuity (OR 7.48, 4.39, 13.1), and location in the Northeast (OR 1.83, 95% CI 1.18, 2.85) and in wealthier counties (OR: 1.32, 95% CI 1.16–1.51) were associated with increased odds of trial participation, while being in counties with more White residents was associated with reduced odds (OR 0.98, 95% CI 0.98–0.99).
Conclusions
Hospitals participating and not participating in COVID-19 inpatient treatment clinical trials differed in many ways, resulting in important implications for the generalizability of trial data.
Funder
National Institutes of Health
Google
National Science Foundation
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Medicine (miscellaneous)
Reference12 articles.
1. COVID-19 Treatment Guidelines Panel. Coronavirus disease 2019 (COVID-19) treatment guidelines. NIH. Accessed 5 Dec 2021. https://www.covid19treatmentguidelines.nih.gov/.
2. Real-world evidence complements randomized controlled trials in clinical decision making | Health Affairs. Accessed 6 Dec 2021. https://www.healthaffairs.org/do/10.1377/hblog20170927.062176/full/.
3. Hong YR, Alishahi Tabriz A, Turner K. Racial and ethnic disparities in clinical trial recruitment in the U.S. Am J Prev Med. 2021;61(5):e245–50. https://doi.org/10.1016/J.AMEPRE.2021.05.007.
4. Chastain DB, Osae SP, Henao-Martínez AF, Franco-Paredes C, Chastain JS, Young HN. Racial disproportionality in COVID clinical trials. N Engl J Med. 2020;383(9):e59. https://doi.org/10.1056/NEJMP2021971.
5. Khazanchi R, Powers SD, Rogawski McQuade ET, McManus KA. Inequities in the geographic accessibility of COVID-19 biomedical therapeutic trials in the United States. J Gen Intern Med. 2021;36(11):3650–3. https://doi.org/10.1007/S11606-021-07081-0/FIGURES/2.